UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-02 | Future report Set alerts | |
| Q2 2022 | 2022-08-08 | -0.27 | -0.27 |
| Q1 2022 | 2022-05-16 | -0.28 | -0.28 |
| Q4 2021 | 2022-03-01 | -0.45 | -0.45 |
| Q3 2021 | 2021-11-04 | -0.21 | -0.21 |
| Q2 2021 | 2021-08-05 | -0.21 | -0.21 |
| Q1 2021 | 2021-05-06 | -1.21 | -1.21 |
| Q4 2020 | 2021-02-25 | -0.19 | -0.19 |
| Q3 2020 | 2020-11-05 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-10 | -0.16 | -0.16 |
| 2016-05-10 | Reiterated Rating | FBR & Co. | Hold | |
| 2016-05-10 | Reiterated Rating | FBR & Co | Hold | |
| 2016-03-01 | Reiterated Rating | Citigroup Inc. | Hold | |
| 2016-02-29 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-02-29 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
| 2016-02-23 | Lower Price Target | William Blair | Market Perform | $12.00 to $8.00 |
| 2016-02-23 | Lower Price Target | FBR & Co. | Market Perform | $14.00 to $10.00 |
| 2016-02-23 | Downgrade | Barclays | Overweight to Equal Weight | $12.00 to $6.00 |
| 2016-02-23 | Downgrade | Barclays PLC | Overweight to Equal Weight | $12.00 to $6.00 |
| 2016-02-22 | Reiterated Rating | Piper Jaffray | Overweight | $18.00 |
| 2016-02-22 | Downgrade | Citigroup Inc. | Buy to Neutral | $13.00 to $9.00 |
| 2016-02-22 | Downgrade | Morgan Stanley | Equal Weight to Underweight | $8.00 to $5.00 |
| 2016-02-19 | Lower Price Target | Citigroup Inc. | $19.00 to $13.00 | |
| 2016-02-10 | Reiterated Rating | FBR & Co. | Market Perform | |
| 2016-02-06 | Reiterated Rating | Citigroup Inc. | Buy | |
| 2016-01-19 | Reiterated Rating | Piper Jaffray | Overweight | $11.00 to $18.00 |
| 2016-01-12 | Reiterated Rating | FBR & Co. | Market Perform | $14.00 |
| 2016-01-04 | Downgrade | William Blair | Hold | |
| 2016-01-04 | Downgrade | JPMorgan Chase & Co. | Hold | |
| 2016-01-04 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-01-03 | Reiterated Rating | Piper Jaffray | Buy | $10.00 to $11.00 |
| 2016-01-03 | Downgrade | Brean Capital | Hold | |
| 2016-01-03 | Downgrade | Cowen and Company | Hold | |
| 2016-01-03 | Reiterated Rating | Citigroup Inc. | Buy | |
| 2016-01-03 | Downgrade | Stifel Nicolaus | Hold | |
| 2015-12-30 | Reiterated Rating | Empire | Equal Weight | |
| 2015-12-30 | Reiterated Rating | Barclays | Buy | |
| 2015-12-30 | Lower Price Target | Janney Montgomery Scott | Neutral | $14.00 |
| 2015-12-29 | Reiterated Rating | Morgan Stanley | Hold | $50.00 to $8.00 |
| 2015-12-29 | Downgrade | William Blair | Outperform to Market Perform | $62.00 to $12.00 |
| 2015-12-29 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $65.00 to $15.00 |
| 2015-12-29 | Lower Price Target | Barclays | Overweight | $65.00 to $12.00 |
| 2015-12-28 | Reiterated Rating | Citigroup Inc. | Buy | $80.00 to $19.00 |
| 2015-12-28 | Downgrade | Cowen and Company | Outperform to Market Perform | $65.00 to $8.00 |
| 2015-12-28 | Downgrade | Brean Capital | Buy to Hold | |
| 2015-12-28 | Reiterated Rating | Piper Jaffray | Overweight | $63.00 to $10.00 |
| 2015-12-28 | Downgrade | FBR & Co. | Outperform to Market Perform | $73.00 to $14.00 |
| 2015-12-28 | Downgrade | Stifel Nicolaus | Buy to Hold | |
| 2015-12-01 | Initiated Coverage | Janney Montgomery Scott | Neutral | $50.00 |
| 2015-12-01 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-11-05 | Reiterated Rating | Brean Capital | Buy | $57.00 |
| 2015-10-27 | Reiterated Rating | William Blair | Buy | $62.00 |
| 2015-10-23 | Reiterated Rating | Piper Jaffray | Overweight | $63.00 |
| 2015-10-23 | Reiterated Rating | Cowen and Company | Outperform | $65.00 |
| 2015-10-11 | Reiterated Rating | William Blair | Outperform | $62.00 |
| 2015-10-05 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $56.00 to $50.00 |
| 2015-09-10 | Reiterated Rating | William Blair | Buy | |
| 2015-09-08 | Reiterated Rating | Cantor Fitzgerald | Buy | $57.00 |
| 2015-09-03 | Initiated Coverage | Citigroup Inc. | Buy | |
| 2015-08-18 | Initiated Coverage | FBR & Co. | Outperform | $73.00 |
| 2015-08-10 | Reiterated Rating | Cantor Fitzgerald | Buy | $57.00 |
| 2015-08-06 | Boost Price Target | Brean Capital | Buy | $50.00 to $57.00 |
| 2015-08-04 | Reiterated Rating | Piper Jaffray | Overweight | $44.00 to $63.00 |
| 2015-07-23 | Reiterated Rating | Piper Jaffray | Buy | $44.00 |
| 2015-05-23 | Reiterated Rating | William Blair | Outperform | $57.00 |
| 2015-05-12 | Reiterated Rating | William Blair | Outperform | $57.00 |
| 2015-05-11 | Set Price Target | Piper Jaffray | Buy | $44.00 |
| 2015-05-11 | Boost Price Target | Brean Capital | Buy | $45.00 to $50.00 |
| 2015-04-15 | Reiterated Rating | Brean Capital | Buy | $45.00 |
| 2015-04-14 | Set Price Target | Piper Jaffray | Buy | $44.00 |
| 2015-03-09 | Reiterated Rating | Cantor Fitzgerald | Buy | $39.00 to $57.00 |
| 2015-03-06 | Set Price Target | Piper Jaffray | Buy | $44.00 |
| 2015-03-06 | Set Price Target | Brean Capital | Buy | $45.00 |
| 2015-03-03 | Initiated Coverage | Barclays | Overweight | $55.00 |
| 2015-02-12 | Boost Price Target | Stifel Nicolaus | Buy | $47.00 to $57.00 |
| 2015-02-03 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $51.00 |
| 2014-12-31 | Boost Price Target | Brean Capital | Buy | $33.00 to $45.00 |
| 2014-10-16 | Boost Price Target | Cantor Fitzgerald | Buy | $33.00 to $39.00 |
| 2014-10-02 | Reiterated Rating | Piper Jaffray | Overweight | $33.00 to $37.00 |
| 2014-09-08 | Initiated Coverage | Cantor Fitzgerald | Buy | $33.00 |
| 2014-08-25 | Lower Price Target | Morgan Stanley | $34.00 to $33.00 | |
| 2014-07-08 | Initiated Coverage | Brean Capital | Buy | $33.00 |
| 2014-06-23 | Initiated Coverage | Brean Capital | Buy | $33.00 |
| 2014-03-13 | Initiated Coverage | Stifel Nicolaus | Buy | $34.00 |
| 2014-03-12 | Reiterated Rating | Morgan Stanley | Overweight | $34.00 |
| 2014-02-13 | Initiated Coverage | Canaccord Genuity | Buy | |
| 2013-11-26 | Initiated Coverage | Piper Jaffray | Overweight | $33.00 |
| 2016-05-10 | Reiterated Rating | FBR & Co. | Hold | |
| 2016-05-10 | Reiterated Rating | FBR & Co | Hold | |
| 2016-03-01 | Reiterated Rating | Citigroup Inc. | Hold | |
| 2016-02-29 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-02-29 | Reiterated Rating | Piper Jaffray Cos. | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CMRX 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Sanderling Venture Partners V, LP | 9.28% (3311400) | CMRX / |
| Hutton Wende S | 7.25% (2584990) | CMRX / DERM / |
| ALTA BIOPHARMA PARTNERS III LP Stockholder | 6.06% (2161829) | AEGR / CARA / CMRX / MGNX / SNSS / |
| CHAMPSI FARAH | 4.81% (1714330) | CMRX / KITE / PTLA / TRVN / |
| New Leaf Ventures II, L.P. | 4.33% (1543394) | CMRX / DRTX / MEIP / VSAR / |
| A.M. Pappas Life Science Ventures IV LP Stockholder | 2.94% (1047535) | CMRX / |
| NIEDEL JAMES | 2.93% (1046082) | CMRX / |
| PAPPAS ARTHUR M | 2.33% (830695) | CMRX / |
| Sanderling Venture Partners VI Co Investment Fund LP | 1.96% (697346) | CMRX / |
| Berrey M Michelle Chief Medical Officer | 0.87% (311336) | CMRX / |
| MARIO ERNEST | 0.81% (288826) | BSX / CAPN / CELG / CMRX / KIN / TNXP / VVUS / XNPT / |
| Trost Timothy W. Sr. Vice President and CFO | 0.31% (111931) | CMRX / |
| Nichols Garrett Chief Medical Officer | 0.27% (96151) | CMRX / |
| Richardson Linda M Chief Commercial Officer | 0.16% (58706) | CMRX / |
| Rogers Michael D. Chief Development Officer | 0.06% (21630) | CMRX / |
| DEMSKI MARTHA J | 0.03% (10000) | ADMS / CMRX / NEOT / |
| Machado Clarence Patrick | 0.03% (10000) | AAVL / CMRX / ECYT / MDVN / SCYX / TKMR / |
| WOLLAEGER TIMOTHY | 0.02% (8702) | CMRX / |
| DRAKE RODMAN L | 0.01% (3500) | CELG / CMRX / |
| Ricciardi Lisa | 0.01% (1950) | CFRX / CMRX / |
UM